CBER Director Peter Marks (Greg Nash/Pool via AP Images)

Fol­low­ing CAR-T safe­ty la­bel changes, FDA of­fi­cials share new de­tails about sec­ondary can­cer cas­es

More than half of the can­cer cas­es the FDA is ex­am­in­ing as part of its CAR-T safe­ty in­ves­ti­ga­tion oc­curred with­in two years of treat­ment, ac­cord­ing to an ed­i­to­r­i­al penned by top FDA of­fi­cials and pub­lished Wednes­day.

The FDA is in­ves­ti­gat­ing 22 cas­es of T cell can­cers de­vel­op­ing af­ter pa­tients un­der­went CAR-T cell ther­a­py treat­ment, the FDA’s Nicole Ver­dun and Pe­ter Marks wrote in the New Eng­land Jour­nal of Med­i­cine. The ed­i­to­r­i­al echoes some of the in­for­ma­tion pre­vi­ous­ly shared by Marks, who over­sees the reg­u­la­tion of cell and gene ther­a­pies at the FDA, at an event ear­li­er this month.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA